[3H]-dehydroepiandrosterone and [14C]-testosterone. The transformation of dehydroepiandrosterone to testosterone and testosterone to 5-dihydrotestosterone were measured. Each type of tissue was capable of performing' these conversions, although some quantitative differences were evident between tissue groups. Nevertheless, it is emphasized that the potentiai for para-endocrine activity is shared by malignant and benign tumours of the breast and normal breast tissue.
STEROID SULPHATION IN VITRO BY HUMAN BREAST CANCER TISSUE. E. MELVILLE and H. BRAUNS-BERG. M.R.C. Clinical Endocrinology Unit, Edinburgh.
The production of (lehydroepiandrosterone (DHAS) and oestradiol sulphate (E2S) was studied in a subcellular fraction prepared from each of 69 primary breast tumours. Steroid sulphation was measured by the method of Dao and Libby (J. cliii. Endocr., 1968, 28, 1431) with minor modifications. The quantity of each steroid sulphate produced by 25 mg wet, wseight tissue during incubation was calculated. Only 40 of 69 tumours were found to effect steroid sulphation. Tumours froin premenopausal women produced significantly more (P = 0.01) of each steroid sulphate than tumours from post-menopausal women. It, has been reported by Dao and Libby (Surgery, 1969, 66, 162) that, a high ratio of DHAS production to E2S production can be associated with a good clinical response to adrenalectomy. The ratio of DHAS production to E2S production was in the range 0-8-1-2 for premenopausal women (n = 9) and in the range 0 4 to 3 8 for post-menopausal women (n = 23). , 1951, 193, 365; Mancini et al., Immunochemistry, 1965, 2, 235) . A standardized dose has been used for skin testing 30 patients with their own tissue extracts. A search was made for precipitating antibodies to tumour extract in the serum of 45 patients by the Ouchterlony double diffusion technique (Ouchterlony, Prog. Allergy, 1958, V, 1).
The mean protein levels in malignant tumours (1-36 mg/ml) were slightly lower than in benign and normal tissues (1-66 mg/ ml). Tissue immunoglobulin levels were significantly reduced in cancer tissue compared with normal and benign tissues, except for IgM which was consistently higher in the malignant tumours. Delayed hypersensitivity reactions were observed in 5000 of patients tested with their own tumour extracts, but were also observed in response to normal tissue and in patients tested with their ow-n benign tumours. Precipitating antibodies in the serum occurred in 110% of cancer patients, but in none of the patients with benign disease of the breast. There have been a number of reports describing antibody to melanoma in approximately 60% of patients with melanoma. However, the technique and the site of fluorescence within the cell have varied.
Sera from melanoma patients were tested against 6 melanoma cell lines by immunofluorescence using cell smears. Results were analysed with regard to the pathological classification of the patients' tumour. No immunofluorescence was detected with sera from patients presenting with tumour restricted to the upper dermis, whereas up to 40% of patients wth tumour spread to the lower dermis were positive. Sera from patients with secondary melanoma showed a higher reactivity.
The cell lines varied in antigenicity and the lines which were most antigenic were also most reactive against normal sera.
If the results were analysed with regard to the number of sera reacting against at least one cell line, then 50% of primary melanoma sera and 90% of secondary melanoma sera were positive.
This indicates that the method of analysis is crucial to the final result, and the current status of serum immunity to melanoma is discussed in this context. Controversy still exists as to whether lymphocyte transformation to phytohaemagglutinin (PHA) is depressed in patients with non-lymphoid malignancies. The need to determine dose response curves in any patient with suspected immune deficiency has
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